12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus.

Conclusion: Preliminary data show that patients treated with incretins and SGLT2-I have not suffered a reduction in cognitive performance during the 1 year of treatment. Metabolic outcome seemed to benefit, in particular, in patients who were treated with SGLT2-I. PMID: 30349407 [PubMed] (Source: Clinical Pharmacology: Advances and Applications)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EMftBr